Trial Profile
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 15 Apr 2024
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Prednisolone (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Dexrazoxane; Doxorubicin; Etoposide; Filgrastim; Filgrastim; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Methylprednisolone; Pegaspargase; Pegaspargase; Prednisolone; Prednisolone; Prednisone; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 06 Mar 2023 Planned End Date changed from 31 Mar 2027 to 30 Sep 2027.
- 06 Mar 2023 Planned primary completion date changed from 31 Mar 2027 to 30 Sep 2027.
- 01 Sep 2022 Planned End Date changed from 31 Mar 2028 to 31 Mar 2027.